Clinical study to evaluate the safety and efficacy of cinnamon in the management of non-alcoholic fatty liver disease

Clinical study to evaluate the safety and efficacy of Darchini (cinnamomum zeylanicum Blume) in the management of non-alcoholic fatty liver disease.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032039

Enrollment

Registered

2021-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Cinnamomum zeylanicum Blume: The drug cinnamomum zeylanicum Blume will be given orally in capsule form in the dosage of 500mg twice daily. Control Intervention1: Vitamin E(tocopherol):

Eligibility

Inclusion criteria

Inclusion criteria: USG documented grade 1 and grade 2 non-alcoholic fatty liver disease. Patients with dull ache/ heaviness in the right hypochondriac region. Patients with symptoms of dyspepsia and malaise. BMI less than 34.9kg/metre square. Patients who are willing to give consent.

Exclusion criteria

Exclusion criteria: Alcoholic liver disease. Grade 3 fatty liver disease and above. Patients with cardiovascular and renal diseases. Patients having focal fatty liver cirrhosis and known cases of hepatitis and other liver morbidities. Patients having cholelithiasis and cholecystitis. BMI greater than 34.9kg/meter square. Pregnant and lactating women. Patients having endocrine disorders like diabetes mellitus. Patients on lipid lowering drugs/statins. Patients who fail to give consent.

Design outcomes

Primary

Measure	Time frame
Relief in signs and symptoms of non alcoholic fatty liver diseaseTimepoint: 60 days	—

Secondary

Measure	Time frame
Radiological and biochemical assessmentTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr zaffar Hussain

Regional Researcvh Institute Of Unani Medicine (RRIUM),University Of Kashmir Srinagar

hussainzaffar6@gmail.com7006021996

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026